glp 1 agonist side effects pancreatitis GLP-1 Agonist Side Effect: Acute Pancreatitis Risk Reconciling GLP-1s and Pancreatitis
Description
Therefore, we decided to conduct a TSA to determine whether sufficient participants were for the outcomes
After 36 weeks, the 0.5 mg retatrutide group showed a 3.19% body weight reduction, the 4 mg group showed a 10.37% decrease, the 8 and 12 mg groups demonstrated decreases of 16.81% and 16.94% respectively, which were significantly greater than those observed with placebo (3.00%) and 1.5 mg dulaglutide (2.02%) [114]
Ann Surg 276(5):e417e424 Goldberg I, Nie L, Yang J, Docimo S, Obici S, Talamini M et al (2021) Impact of bariatric surgery on the development of diabetic microvascular and macrovascular complications
Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target mendelian randomization and clinical trials
